Xiangxue Pharmaceutical Co.,Ltd. Stock

Equities

300147

CNE100000Y92

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
3.67 CNY -1.87% Intraday chart for Xiangxue Pharmaceutical Co.,Ltd. +1.38% -28.74%

Financials

Sales 2022 2.19B 302M 413M Sales 2023 2.3B 318M 435M Capitalization 3.41B 470M 644M
Net income 2022 -533M -73.62M -101M Net income 2023 -389M -53.73M -73.54M EV / Sales 2022 2.86 x
Net Debt 2022 2.29B 316M 433M Net Debt 2023 2.28B 315M 432M EV / Sales 2023 2.47 x
P/E ratio 2022
-7.49 x
P/E ratio 2023
-8.73 x
Employees 2,417
Yield 2022 *
-
Yield 2023
-
Free-Float 37.6%
More Fundamentals * Assessed data
Dynamic Chart
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Ji Qingsong agreed to acquire 18.87% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 200 million. CI
Xiangxue Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 959.884 million in funding CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Xiangxue Pharma Trims Losses in 2022 MT
China's COVID scare sparks run on flu medicines, test kits as far away as Australia RE
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Wuhan Yiyi Tongguan Enterprise Management Partnership (Limited Partnership) and Hubei Qingsong Yueyue Pharmaceutical Co., Ltd. agreed to acquire 35% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 385 million. CI
Xiangxue Pharmaceutical Co.,Ltd. Approves Board Elections CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day-1.87%
1 week+1.38%
1 month-15.63%
3 months-1.08%
6 months-33.27%
Current year-28.74%
More quotes
1 week
3.60
Extreme 3.6
3.76
1 month
3.32
Extreme 3.32
4.19
Current year
3.00
Extreme 3
5.35
1 year
3.00
Extreme 3
6.45
3 years
3.00
Extreme 3
9.79
5 years
3.00
Extreme 3
14.48
10 years
3.00
Extreme 3
51.41
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 97-12-15
Chairman 53 05-10-31
Chief Tech/Sci/R&D Officer 47 19-06-27
Members of the board TitleAgeSince
Chief Executive Officer 62 97-12-15
Director/Board Member 57 12-03-27
Director/Board Member 51 22-06-23
More insiders
Date Price Change Volume
24-04-30 3.67 -1.87% 13,332,250
24-04-29 3.74 +3.60% 13,754,280
24-04-26 3.61 -0.28% 8,034,628
24-04-25 3.62 +1.12% 8,187,633

End-of-day quote Shenzhen S.E., April 29, 2024

More quotes
XIANGXUE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the research, development, production and distribution of traditional Chinese medicines and herbal decoction pieces. The Company's main products include antiviral oral liquids, indigowoad root granules, Exocarpium Citri Reticulatae series Chinese patent drugs and herbal decoction pieces, among others. The Company is also involved in the manufacture and sale of medical devices, health products, soft drinks and biological products. The Company distributes its products in domestic market.
More about the company
  1. Stock Market
  2. Equities
  3. 300147 Stock